12 September 2025

RheumNow Podcast – Ro, Ro, Ro52 (9.12.2025)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Are there benefits to diet or vegan diets? What's the effect of menopause on CTD? Ro52 makes a big entrance with all our ILD coverage this month.

Ro, Ro, Ro52 (9.12.2025)

Japanese retrospective real world study shows antifibrotic use assoc w/ better survival in Pulm Fibrosis-ILD for 1st 3

Tweet Author

RheumNow

Tweet Content

Japanese retrospective real world study shows antifibrotic use assoc w/ better survival in Pulm Fibrosis-ILD for 1st 3 yrs & improved survival in progressive pulm. fibrosis (PPF) “despite management” (PPF subset prev Rx non-antifibrotic therapy) https://t.co/caiIuhg7j8 https://t.co/N0ST73TMoR

Links

https://buff.ly/4nhpTUS

3 yr study of FDA Adverse Event Reporting on anifrolumab shows following AEs- URIs, herpes zoster, infusion reactions,

Tweet Author

RheumNow

Tweet Content

3 yr study of FDA Adverse Event Reporting on anifrolumab shows following AEs- URIs, herpes zoster, infusion reactions, and potential new risks like dyspnea and pyrexia, not in the label. https://t.co/vP2YWGT2vR https://t.co/BruGBtXEBu

Links

Post-marketing safety signals of anifrolumab in systemic lupus erythematosus: a… https://buff.ly/vgJoe8I

11 September 2025

SMART study - Single vs. Split Dose Methotrexate in RA

Split dose weekly, oral methotrexate (MTX) was shown to be superior to single dose MTX in treating active rheumatoid arthritis (RA) patients.

Sjogren's Disease Interstitial Lung Disease Dr. Nancy Carteron, a rheumatologist in northern California, discusses int

Tweet Author

RheumNow

Tweet Content

Sjogren's Disease Interstitial Lung Disease Dr. Nancy Carteron, a rheumatologist in northern California, discusses interstitial lung disease in Sjogren's disease, as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025. https://t.co/lA1vrBiar4

11 September 2025

How to assess ILD in your patients?

Have a high index of suspicion in your patients with connective tissue disease (especially systemic sclerosis, inflammatory myositis), and rheumatoid arthritis.

Single center study of 47 RA-ILD pts (Dx Age 64.7 yrs; 30 mos F/U). Median 100 mos from RA Dx to RA-ILD. Nearly half (49

Tweet Author

RheumNow

Tweet Content

Single center study of 47 RA-ILD pts (Dx Age 64.7 yrs; 30 mos F/U). Median 100 mos from RA Dx to RA-ILD. Nearly half (49%) recv Rx for RA-ILD; few w/ TCZ, nintedanib, pirfenidone. ~90% had RA-ILD stability/improve @ 6 & 12 mos. Progression assoc w/ tobacco use (P .025) @ 6 mos https://t.co/AK4zYgcxeK

Regional Disparities in DMARD Management for RA Treatment Dr. Aurelie Najm, Glasgow, reports on a session on "Updates

Tweet Author

RheumNow

Tweet Content

Regional Disparities in DMARD Management for RA Treatment Dr. Aurelie Najm, Glasgow, reports on a session on "Updates on DMARDs treatment: global standards and regional adaptations" from the APLAR 2025 Congress in Fukuoka, Japan. https://t.co/zDo5NxKtbE https://t.co/kF9FxyWkIQ

Links

Regional Disparities in DMARD Management for RA Treatment | RheumNow https://buff.ly/Mc0MPHB

Italian Systemic sclerosis (SPRING-SIR) registry - 1157/1538 (75%) SSc pts were in menopause, 632 (50%) had pre-menop SS

Tweet Author

RheumNow

Tweet Content

Italian Systemic sclerosis (SPRING-SIR) registry - 1157/1538 (75%) SSc pts were in menopause, 632 (50%) had pre-menop SSc onset, 130 (14.4%) had early menopause. Post-menop. had more CREST, centromere Abs, ILD & GI Sxs. Pre-menop. had more diffuse Dz & peripheral vasculopathy. https://t.co/Jz2v5CkH0Y

Topics

RheumNow Podcast – Ro, Ro, Ro52 (9.12.2025)

Ro, Ro, Ro52 (9.12.2025)

Japanese retrospective real world study shows antifibrotic use assoc w/ better survival in Pulm Fibrosis-ILD for 1st 3

3 yr study of FDA Adverse Event Reporting on anifrolumab shows following AEs- URIs, herpes zoster, infusion reactions,

Sjogren's Disease Interstitial Lung Disease Dr. Nancy Carteron, a rheumatologist in northern California, discusses int

Single center study of 47 RA-ILD pts (Dx Age 64.7 yrs; 30 mos F/U). Median 100 mos from RA Dx to RA-ILD. Nearly half (49

Regional Disparities in DMARD Management for RA Treatment Dr. Aurelie Najm, Glasgow, reports on a session on "Updates

Italian Systemic sclerosis (SPRING-SIR) registry - 1157/1538 (75%) SSc pts were in menopause, 632 (50%) had pre-menop SS

Do you get our email newsletter?